SARS-CoV-2 Protease Assay Services
In today’s global COVID-19 pandemic crisis, protease studies are more important than ever, since proteases are essential for virus replication of coronaviruses. Existing protease inhibitors are now being added to clinical trials for target SARS-CoV-2 and specific proteases have been under special investigation as new strategical targets to prevent and cure coronavirus infections. These targets include ACE2, TMPRSS2 protease, and Main Protease (Mpro protease or 3CL protease) which are indispensable for virus replication and the infection process.
To support the drug discovery community in the challenge to identify efficacious COVID-19 drugs, we have developed specific assays targeting proteases that are essential for SARS-CoV-2 virus entry and replication.
- Fluorescence-based protease activity assays for inhibitor screening
- Low and large scale, as well as high-throughput protease inhibitor screening options, are available
- Full protease panel screening is available for off-target analysis.
Reaction Biology supports the global quest for relief from COVID-19 through offering SARS-CoV-2 Protease Screening Services to accurately determine the potency of potential therapeutics to inhibit host and viral proteases.
Our research organization has two facilities: one in the United States and another in Germany. With a strong presence on both sides of the Atlantic, we’re easily accessible by pharmaceutical companies and drug discovery researchers around the world in need of COVID-19 protease assays.
